Ben-Gurion University of the Negev Deploys Rosetta Systems for a Pilot Study in Bioinformatics
News Feb 14, 2007
Rosetta Biosoftware has announced that the Rosetta Elucidator® system for LC/MS protein expression analysis and the Rosetta Resolver® system for gene expression data analysis will be used for the study of Bioinformatics at the National Institute of Biotechnology in the Negev (NIBN) at Ben-Gurion University of the Negev.
Headed by Eitan Rubin, Ph.D., from the NIBN and Department of Microbiology and Immunology, the computational biotechnology team will use these systems as a pilot study aimed at establishing a National Test Bed that will allow researchers throughout Israel to evaluate software and databases for biotechnology research.
The systems will also be used in a research program lead by researchers from the Weizmann Institute of Science, in which plant response to stress is being studied.
"We are very excited about the opportunities that the Rosetta Resolver and Elucidator systems open for us," said Eitan Rubin, Ph.D., who leads the pilot project.
"The combination of industrial strength and ease-of-use that both systems offer allow us to create a resource that will not only help us in research, but one that we hope could be used by the entire research community in Israel," said Rubin.
“We are pleased to provide the Resolver and Elucidator systems for a pilot study to Ben-Gurion University, and to have our product be considered for a National Test Bed program,” said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware.
Shevelenko continued, “The integration capabilities built into our products will be valuable for enabling the cross-platform research that is being done at Ben-Gurion University. We are honored to support their systems biology research and provide the university with the robust data management and analysis capabilities for gene expression and comparative proteomics research.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.